Developer docs
API playgroundTry for free, no card

Search company profiles

Biobank

Full company profile

uuid000bd4h

Namestring
Biobank
Legal namestring
SAS BIOBank
Websiteurl
biobank.fr
Company typeenum
Private
Founded yearint
1999
Descriptiontext

BIOBank (legal entity SAS BIOBank) is a French specialty medical device company founded in 1999 and headquartered in Lieusaint, France, that manufactures and distributes human bone allografts. Its core technology is the proprietary Supercrit® process, which applies supercritical CO2 delipidation combined with chemical oxidation of residual proteins to bone tissue harvested from living donors; the process preserves the native mineral-collagen structure and biomechanical properties of bone while delivering validated viral inactivation exceeding the SAL 10^-6 regulatory threshold across a broad virus panel (validated independently by the Pasteur Institute and Texcell). The company sells a comprehensive orthopaedic/spine portfolio — whole and half femoral heads, wedges, cancellous blocks, dowels, granules, and powder-in-syringe formats — and a dental/maxillofacial portfolio including cancellous and cortico-cancellous powders, cortical plates, and patient-specific customized grafts produced from CT/Cone-Beam imaging with 3D modeling and printing.

BIOBank distributes its products exclusively against nominative medical prescription to orthopaedic, spine, dental and maxillofacial surgeons in hospitals, clinics and private practices via a direct sales motion with dedicated phone lines per segment. Revenue is generated through one-time purchases of graft units at undisclosed list pricing; there is no subscription, recurring, or licensing revenue stream. The company holds ANSM authorization (since 2003), was the first tissue bank globally to obtain ISO 13485 certification for bone allografts, and is FDA registered, supporting both domestic dominance (>50% French market share) and stated international expansion ambitions. Following the May 2024 sale of a majority stake to IK Partners' IK Small Cap III Fund (with management reinvesting), BIOBank is positioned to scale market share, expand internationally, and develop new products.

Short descriptiontext

BIOBank is a French manufacturer and distributor of viro-inactivated human bone allografts, processed via its proprietary Supercrit® supercritical CO2 technology, serving orthopaedic, spine, and dental/maxillofacial surgeons on nominative medical prescription; it holds over 50% French market share, is the first tissue bank ISO 13485-certified for bone allografts, and is FDA registered.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLieusaint, France
HQ citystring
Lieusaint
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bone allografts, tissue banking, orthopedic surgical products, dental bone grafts, viro-inactivated grafts
Industry2 codes
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLABAEAB
Dental Implant Surgery & Bone Grafting
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Bone Allografts / Tissue Banking
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Bone Allograft Products
TypeOne Time License
Description

BIOBank manufactures and distributes a range of processed bone allograft products (femoral head grafts, wedges, blocks, granules, powders, custom grafts) to orthopaedic, spine, and oral/maxillofacial surgeons. Products are sold as one-time purchases against nominative medical prescriptions, with no subscription or recurring revenue model.

biobank.fr
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Supercrit®
Description

Proprietary bone tissue treatment process based on supercritical CO2 delipidation combined with chemical oxidation for viral inactivation of bone allografts.

biobank.fr
Core offering1 text field

BIOBank manufactures and distributes viro-inactivated human bone allografts processed through its patented Supercrit® supercritical CO2 process for orthopaedic, spine and oral/maxillofacial surgeons in France. The product range covers whole and half femoral heads, wedges, cancellous blocks, dowels, granules, powders (in vial and syringe presentations), cortical plates, cortico-cancellous plates and CT/Cone-Beam-customised grafts. All products are delivered sterile in double airtight packaging with a five-year shelf life and sold exclusively on nominative medical prescription.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 95.3% successful cervical fusion and 90.5% lumbar fusion rates using Supercrit® allografts, with >80% of patients reporting good to excellent outcomes per Odom's scores
+2 more records
Product overview1 text field

BIOBank is a French manufacturer and distributor of bone allografts for orthopedic, spine, dental, and cranio-maxillofacial surgery. The company offers a comprehensive portfolio of products derived from human femoral heads harvested exclusively from living donors in France. All products are processed using the proprietary Supercrit® process, which uses supercritical CO2 for delipidation combined with chemical oxidation for viral inactivation. The orthopedic/spine range includes whole and half femoral heads, bone wedges, cancellous blocks, bone dowels, granules, and powder in various presentations. The dental range includes cancellous and cortico-cancellous bone powders, cortical plates, and the innovative Customized Bone Graft prepared from CT-scan/Cone-Beam imaging. The company holds ISO 13485 certification and FDA registration, commanding over 50% market share in France.

Product and service13 records
1Whole Femoral Head Allograft
CategoryOrthopaedic / Spine Bone Allografts
Description

Complete femoral head bone allograft for filling segmental bone loss and structural grafts in arthroplasty revisions, tumour curettage, fracture osteosynthesis, osteotomy and spinal arthrodesis procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.

2Half Femoral Head Allograft
CategoryOrthopaedic / Spine Bone Allografts
Description

Half femoral head allograft for filling segmental bone loss and structural grafts in orthopaedic and spinal procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.

3Bone Wedge
CategoryOrthopaedic / Spine Bone Allografts
Description

Bone wedges available in 6mm to 14mm sizes for structural bone grafting and spinal arthrodesis procedures.

4Cancellous Bone Block
CategoryOrthopaedic / Spine Bone Allografts
Description

Cancellous bone blocks in various dimensions used to fill bone loss and provide structural grafts in orthopaedic procedures.

5Cancellous Bone Dowels
CategoryOrthopaedic / Spine Bone Allografts
Description

Cancellous bone dowels in 9mm to 14mm diameters primarily used for ligamentoplasty reconstruction procedures.

6Cancellous Bone Granules
CategoryOrthopaedic / Spine Bone Allografts
Description

Cancellous bone granules supplied in vials or syringes at 7cc, 18cc or 25cc volumes for filling bone defects in orthopaedic and spinal procedures.

7Cancellous Bone Powder in Syringe
CategoryOrthopaedic / Spine Bone Allografts
Description

Cancellous bone powder supplied in a specifically designed syringe with luer-lock connector for semi-closed rehydration with sterile sodium chloride solution, enabling direct aseptic dispensing into the grafting site. Available in 0.5cc, 1cc and 2cc volumes.

8Cancellous Bone Powder (Dental)
CategoryDental / Maxillofacial Bone Allografts
Description

Cancellous bone powder in vial presentation available in S (0.5mm) and L (1mm) granulometries for dental and maxillofacial procedures including peri-implant filling, sinus floor elevation and extraction socket filling.

9Cortico-Cancellous Bone Powder (Dental)
CategoryDental / Maxillofacial Bone Allografts
Description

Cortico-cancellous bone powder for dental applications including peri-implant filling, sinus floor elevation and extraction socket filling.

10Cortical Bone Plates
CategoryDental / Maxillofacial Bone Allografts
Description

Cortical bone plates available in 12x10mm and 18x10mm sizes for guided bone regeneration as an alternative to autologous grafts before dental implant placement.

11Cortico-Cancellous Plates
CategoryDental / Maxillofacial Bone Allografts
Description

Cortico-cancellous plates in 15x10x4mm and 22x12x4mm sizes for dental and maxillofacial reconstruction procedures.

12Cancellous Bone Block (Dental)
CategoryDental / Maxillofacial Bone Allografts
Description

Cancellous bone block in 20x10x10mm dimensions used for autologous harvest site regeneration in dental procedures.

13Customized Bone Graft (Greffon sur mesure)
CategoryDental / Maxillofacial Bone Allografts
Description

Custom-designed bone graft prepared from CT-scan or Cone-Beam imaging using 3D modelling and printing, available in cortico-cancellous or cancellous types, pre-machined to match patient anatomy. Enables pre-operative planning on a 3D silicone model, reducing surgical time and improving graft-host bone congruence, and processed through the same Supercrit® workflow as standard BIOBank grafts.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

BIOBank partnered with the Pasteur Institute (studies in 1995 and 2003) and its spin-off Texcell (study in 2022) to scientifically validate the viral inactivation efficacy of the Supercrit® process. These studies demonstrated that the process exceeds the Security Assurance Level of 10^-6 across multiple virus categories including HIV, HCV, HBV, Parvovirus, and SARS-CoV-2.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global orthopedic reconstruction leader with bone graft and biologics offerings across joint reconstruction, spine, and dental. Broad incumbent competing in the same surgical indications where Biobank's allografts are used.

TypeDirect peer
Description

US non-profit tissue bank manufacturing allografts for orthopedic, spine, and dental reconstruction. Direct peer in the bone allograft category with overlapping customer base of surgeons and hospitals.

TypeDirect peer
Description

One of the largest global tissue banks providing allograft bone and other musculoskeletal grafts for orthopedic, spine, and dental procedures. Direct competitor to Biobank in the bone allograft category with overlapping surgeon customers and similar regulatory positioning.

TypeDirect peer
Description

US-based non-profit tissue bank and one of the world's largest providers of bone, cartilage, and soft tissue allografts. Competes directly with Biobank in bone allografts and serves many of the same orthopedic and spine surgery indications.

TypeBroad incumbent
Description

Global orthopedics and medical devices incumbent offering bone graft substitutes (including synthetic and biologics portfolios) and orthopedic surgical products. Competes with Biobank through breadth of orthopedic offerings and scale advantages.

TypeDirect peer
Description

US-listed developer and manufacturer of regenerative medicine products including bone allografts for spine and orthopedic surgery. Direct competitor in the bone allograft space with comparable hospital-channel GTM.

TypeBroad incumbent
Description

Global medical device leader with the Infuse Bone Graft (rhBMP-2) product, a dominant bone graft substitute in spinal fusion. Represents the largest competitive threat to Biobank's spine business through an entirely synthetic alternative with global commercial reach.

TypeDirect peer
Description

US-based company with a meaningful bone allograft and spine portfolio alongside 3D-printed implant capabilities. Direct competitor in bone allografts and increasingly in customized implants—an area where Biobank's "Greffon sur mesure" competes.

TypeDirect peer
Description

Swiss-headquartered leader in dental bone regeneration with the Bio-Oss and Bio-Gide lines used in sinus lifts, peri-implant grafting, and guided bone regeneration. Direct competitor in Biobank's dental/maxillofacial bone graft segment, particularly in European markets.

10botiss biomaterials
TypeEmerging player
Description

European (German) dental bone and soft tissue regeneration specialist offering allograft, xenograft, and synthetic bone graft substitutes. Competes with Biobank's dental range and shares a European sales footprint focused on implantology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Biobank

Bone Allografts / Tissue Bankingbiobank.fr

BIOBank is a French manufacturer and distributor of viro-inactivated human bone allografts, processed via its proprietary Supercrit® supercritical CO2 technology, serving orthopaedic, spine, and dental/maxillofacial surgeons on nominative medical prescription; it holds over 50% French market share, is the first tissue bank ISO 13485-certified for bone allografts, and is FDA registered.

What Biobank does

BIOBank (legal entity SAS BIOBank) is a French specialty medical device company founded in 1999 and headquartered in Lieusaint, France, that manufactures and distributes human bone allografts. Its core technology is the proprietary Supercrit® process, which applies supercritical CO2 delipidation combined with chemical oxidation of residual proteins to bone tissue harvested from living donors; the process preserves the native mineral-collagen structure and biomechanical properties of bone while delivering validated viral inactivation exceeding the SAL 10^-6 regulatory threshold across a broad virus panel (validated independently by the Pasteur Institute and Texcell). The company sells a comprehensive orthopaedic/spine portfolio — whole and half femoral heads, wedges, cancellous blocks, dowels, granules, and powder-in-syringe formats — and a dental/maxillofacial portfolio including cancellous and cortico-cancellous powders, cortical plates, and patient-specific customized grafts produced from CT/Cone-Beam imaging with 3D modeling and printing.

BIOBank distributes its products exclusively against nominative medical prescription to orthopaedic, spine, dental and maxillofacial surgeons in hospitals, clinics and private practices via a direct sales motion with dedicated phone lines per segment. Revenue is generated through one-time purchases of graft units at undisclosed list pricing; there is no subscription, recurring, or licensing revenue stream. The company holds ANSM authorization (since 2003), was the first tissue bank globally to obtain ISO 13485 certification for bone allografts, and is FDA registered, supporting both domestic dominance (>50% French market share) and stated international expansion ambitions. Following the May 2024 sale of a majority stake to IK Partners' IK Small Cap III Fund (with management reinvesting), BIOBank is positioned to scale market share, expand internationally, and develop new products.

Biobank firmographics

Firmographics
Name
Biobank
Legal name
SAS BIOBank
Website
https://biobank.fr
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
11–50 employees
Short description
BIOBank is a French manufacturer and distributor of viro-inactivated human bone allografts, processed via its proprietary Supercrit® supercritical CO2 technology, serving orthopaedic, spine, and dental/maxillofacial surgeons on nominative medical prescription; it holds over 50% French market share, is the first tissue bank ISO 13485-certified for bone allografts, and is FDA registered.
Ownership category
akta.pro rank

Biobank industry classification

Industry
Product category
Bone Allografts / Tissue Banking
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAG
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLABAEAB
Dental Implant Surgery & Bone Grafting

Keywords

  • Bone allografts
  • Tissue banking
  • Orthopedic surgical products
  • Dental bone grafts
  • Viro-inactivated grafts

Where Biobank is headquartered

Location

Headquarters

HQ city
Lieusaint
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Biobank business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Bone Allograft Products: BIOBank manufactures and distributes a range of processed bone allograft products (femoral head grafts, wedges, blocks, granules, powders, custom grafts) to orthopaedic, spine, and oral/maxillofacial surgeons. Products are sold as one-time purchases against nominative medical prescriptions, with no subscription or recurring revenue model.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Biobank product offering

Product offering

Core offering

BIOBank manufactures and distributes viro-inactivated human bone allografts processed through its patented Supercrit® supercritical CO2 process for orthopaedic, spine and oral/maxillofacial surgeons in France. The product range covers whole and half femoral heads, wedges, cancellous blocks, dowels, granules, powders (in vial and syringe presentations), cortical plates, cortico-cancellous plates and CT/Cone-Beam-customised grafts. All products are delivered sterile in double airtight packaging with a five-year shelf life and sold exclusively on nominative medical prescription.

Product overview

BIOBank is a French manufacturer and distributor of bone allografts for orthopedic, spine, dental, and cranio-maxillofacial surgery. The company offers a comprehensive portfolio of products derived from human femoral heads harvested exclusively from living donors in France. All products are processed using the proprietary Supercrit® process, which uses supercritical CO2 for delipidation combined with chemical oxidation for viral inactivation. The orthopedic/spine range includes whole and half femoral heads, bone wedges, cancellous blocks, bone dowels, granules, and powder in various presentations. The dental range includes cancellous and cortico-cancellous bone powders, cortical plates, and the innovative Customized Bone Graft prepared from CT-scan/Cone-Beam imaging. The company holds ISO 13485 certification and FDA registration, commanding over 50% market share in France.

Differentiator

Problem solved

Functional benefit

Brands

  • Supercrit®: Proprietary bone tissue treatment process based on supercritical CO2 delipidation combined with chemical oxidation for viral inactivation of bone allografts.

Products and services

  • Whole Femoral Head Allograft Complete femoral head bone allograft for filling segmental bone loss and structural grafts in arthroplasty revisions, tumour curettage, fracture osteosynthesis, osteotomy and spinal arthrodesis procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.
  • Half Femoral Head Allograft Half femoral head allograft for filling segmental bone loss and structural grafts in orthopaedic and spinal procedures. Sold to orthopaedic and spine surgeons on nominative medical prescription.
  • Bone Wedge Bone wedges available in 6mm to 14mm sizes for structural bone grafting and spinal arthrodesis procedures.
  • Cancellous Bone Block Cancellous bone blocks in various dimensions used to fill bone loss and provide structural grafts in orthopaedic procedures.
  • Cancellous Bone Dowels Cancellous bone dowels in 9mm to 14mm diameters primarily used for ligamentoplasty reconstruction procedures.
  • Cancellous Bone Granules Cancellous bone granules supplied in vials or syringes at 7cc, 18cc or 25cc volumes for filling bone defects in orthopaedic and spinal procedures.
  • Cancellous Bone Powder in Syringe Cancellous bone powder supplied in a specifically designed syringe with luer-lock connector for semi-closed rehydration with sterile sodium chloride solution, enabling direct aseptic dispensing into the grafting site. Available in 0.5cc, 1cc and 2cc volumes.
  • Cancellous Bone Powder (Dental) Cancellous bone powder in vial presentation available in S (0.5mm) and L (1mm) granulometries for dental and maxillofacial procedures including peri-implant filling, sinus floor elevation and extraction socket filling.
  • Cortico-Cancellous Bone Powder (Dental) Cortico-cancellous bone powder for dental applications including peri-implant filling, sinus floor elevation and extraction socket filling.
  • Cortical Bone Plates Cortical bone plates available in 12x10mm and 18x10mm sizes for guided bone regeneration as an alternative to autologous grafts before dental implant placement.
  • Cortico-Cancellous Plates Cortico-cancellous plates in 15x10x4mm and 22x12x4mm sizes for dental and maxillofacial reconstruction procedures.
  • Cancellous Bone Block (Dental) Cancellous bone block in 20x10x10mm dimensions used for autologous harvest site regeneration in dental procedures.
  • Customized Bone Graft (Greffon sur mesure) Custom-designed bone graft prepared from CT-scan or Cone-Beam imaging using 3D modelling and printing, available in cortico-cancellous or cancellous types, pre-machined to match patient anatomy. Enables pre-operative planning on a 3D silicone model, reducing surgical time and improving graft-host bone congruence, and processed through the same Supercrit® workflow as standard BIOBank grafts.

Quantifiable outcome

  • 95.3% successful cervical fusion and 90.5% lumbar fusion rates using Supercrit® allografts, with >80% of patients reporting good to excellent outcomes per Odom's scores
  • +2 more outcomes

Companies that use Biobank

Customer profile

Segments2 records

Ideal customer profiles2 records

Biobank technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Biobank partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Pasteur Institute / TexcellcoreStrategic or Co-development PartnerBIOBank partnered with the Pasteur Institute (studies in 1995 and 2003) and its spin-off Texcell (study in 2022) to scientifically validate the viral inactivation efficacy of the Supercrit® process. These studies demonstrated that the process exceeds the Security Assurance Level of 10^-6 across multiple virus categories including HIV, HCV, HBV, Parvovirus, and SARS-CoV-2.

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Biobank competitors and assessment

Company assessment

Broad incumbents

  • Zimmer Biomet: Global orthopedic reconstruction leader with bone graft and biologics offerings across joint reconstruction, spine, and dental. Broad incumbent competing in the same surgical indications where Biobank's allografts are used.
  • Stryker: Global orthopedics and medical devices incumbent offering bone graft substitutes (including synthetic and biologics portfolios) and orthopedic surgical products. Competes with Biobank through breadth of orthopedic offerings and scale advantages.
  • Medtronic: Global medical device leader with the Infuse Bone Graft (rhBMP-2) product, a dominant bone graft substitute in spinal fusion. Represents the largest competitive threat to Biobank's spine business through an entirely synthetic alternative with global commercial reach.

Direct peers

  • AlloSource: US non-profit tissue bank manufacturing allografts for orthopedic, spine, and dental reconstruction. Direct peer in the bone allograft category with overlapping customer base of surgeons and hospitals.
  • LifeNet Health: One of the largest global tissue banks providing allograft bone and other musculoskeletal grafts for orthopedic, spine, and dental procedures. Direct competitor to Biobank in the bone allograft category with overlapping surgeon customers and similar regulatory positioning.
  • MTF Biologics: US-based non-profit tissue bank and one of the world's largest providers of bone, cartilage, and soft tissue allografts. Competes directly with Biobank in bone allografts and serves many of the same orthopedic and spine surgery indications.
  • Xtant Medical: US-listed developer and manufacturer of regenerative medicine products including bone allografts for spine and orthopedic surgery. Direct competitor in the bone allograft space with comparable hospital-channel GTM.
  • restor3d (formerly RTI Surgical): US-based company with a meaningful bone allograft and spine portfolio alongside 3D-printed implant capabilities. Direct competitor in bone allografts and increasingly in customized implants—an area where Biobank's "Greffon sur mesure" competes.
  • Geistlich Pharma: Swiss-headquartered leader in dental bone regeneration with the Bio-Oss and Bio-Gide lines used in sinus lifts, peri-implant grafting, and guided bone regeneration. Direct competitor in Biobank's dental/maxillofacial bone graft segment, particularly in European markets.

Emerging players

  • botiss biomaterials: European (German) dental bone and soft tissue regeneration specialist offering allograft, xenograft, and synthetic bone graft substitutes. Competes with Biobank's dental range and shares a European sales footprint focused on implantology.

Market position

Strengths5 records

Weaknesses3 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Biobank compliance and trust

Trust signal

Compliance3 records

Biobank financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Biobank leadership team

Management profile

Number of profiles

Profiles2 records

Biobank funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Biobank M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biobank

What does Biobank do?

BIOBank manufactures and distributes viro-inactivated human bone allografts processed through its patented Supercrit® supercritical CO2 process for orthopaedic, spine and oral/maxillofacial surgeons in France. The product range covers whole and half femoral heads, wedges, cancellous blocks, dowels, granules, powders (in vial and syringe presentations), cortical plates, cortico-cancellous plates and CT/Cone-Beam-customised grafts. All products are delivered sterile in double airtight packaging with a five-year shelf life and sold exclusively on nominative medical prescription.

Is Biobank a public or private company?

Biobank is a private company. It is classified as private equity controlled and is currently operating.

When was Biobank founded?

Biobank was founded in 1999. It employs 11 to 50 people.

Where is Biobank based?

Biobank is headquartered in Lieusaint, France, in the Europe region.

How does Biobank make money?

One revenue line is on record: bone Allograft Products.

Who are Biobank's main competitors?

Broad incumbents on record are Zimmer Biomet, Stryker and Medtronic. Direct peers are AlloSource, LifeNet Health, MTF Biologics, Xtant Medical, restor3d (formerly RTI Surgical) and Geistlich Pharma. botiss biomaterials is listed as an emerging player.

Does Biobank have an API?

No public API is recorded for Biobank.

What industry is Biobank in?

Biobank's product category is Bone Allografts / Tissue Banking. Its primary akta.pro industry code is HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM), with a secondary code of HLABAEAB, Dental Implant Surgery & Bone Grafting. Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
InvestorsinhealthcareFrance: IK acquires majority stake in BIOBank from management, Verto Growth and Capital CroissanceIK Partners is acquiring a majority stake in France-based BIOBank, a manufacturer and distributor of bone allografts for various surgical procedures. The acquisition involves buying out shares from current owners including management, Verto Growth, and Capital Croissance.IkpartnersIK Partners to invest in BIOBank alongside Management and historical shareholders Verto Growth and Capital CroissanceIK Partners has signed an agreement to invest in BIOBank, a manufacturer and distributor of bone allografts, acquiring a majority stake from Verto Growth, Capital Croissance, and the management team. BIOBank, which holds over 50% market share in France, aims to enhance its distribution network and pursue further international expansion with IK's support. The transaction marks a new chapter in BIOBank's growth trajectory as it looks to reinforce its leadership and innovate in the bone allograft market.DeepAIConformalized Survival AnalysisA conformalized survival analysis method wraps any survival prediction algorithm to produce calibrated, covariate-dependent lower predictive bounds on survival times. Under Type I right-censoring with exogenous censoring, bounds have guaranteed finite-sample coverage; under conditional independence, they are doubly robust. The method is validated on synthetic data and UK Biobank COVID-19 data.BBCCovid: UK Biobank scans aim to reveal health legacyUK Biobank scientists are scanning about 1,500 people who had Covid-19 and 1,500 controls to assess long-term organ effects. The study will compare pre- and post-pandemic data, including brain scans, to investigate neurological changes. Results will be shared with researchers globally.UnquoteNewAlpha Verto holds first close for maiden fundNewAlpha Verto Capital held a €100m first close for its maiden fund, with a €150m second close planned for mid-2019. The fund targets profitable SMEs with turnover of at least €10m and growth over 10%, and its first investment was Biobank.UnquoteCapital Croissance exits BioBankCapital Croissance sold its majority stake in BioBank to NewAlpha Verto Capital and management, with BPI France providing debt support. The deal yielded a 4-4.5x return on investment, and Capital Croissance will reinvest by acquiring a minority holding. BioBank's revenues rose from €6m in 2014 to €12m in 2017.PR NewswireGlobal Biobanking Market 2016-2020Technavio forecasts the global biobanking market to grow at an 8% CAGR from 2016-2020, driven by biobanks' role in sample collection and storage. The equipment segment holds over 74% of the market, and EMEA accounts for about 44% of the share, with human tissues representing 65% of sample-type demand.